CA2903933C - Methodes et compositions de conditionnement d'acides nucleiques dans les exosomes microgliaux destines a l'expression ciblee de polypeptides dans les cellules neuronales - Google Patents

Methodes et compositions de conditionnement d'acides nucleiques dans les exosomes microgliaux destines a l'expression ciblee de polypeptides dans les cellules neuronales Download PDF

Info

Publication number
CA2903933C
CA2903933C CA2903933A CA2903933A CA2903933C CA 2903933 C CA2903933 C CA 2903933C CA 2903933 A CA2903933 A CA 2903933A CA 2903933 A CA2903933 A CA 2903933A CA 2903933 C CA2903933 C CA 2903933C
Authority
CA
Canada
Prior art keywords
nucleic acid
polypeptide
acid sequence
seq
sequence encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2903933A
Other languages
English (en)
Other versions
CA2903933A1 (fr
Inventor
Scott Allan Wong
Evan Anthony Caton
Zakery Kevin Stinson
Aubrey Marissa Demchuk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nomadogen Biotechnologies Inc
Original Assignee
Nomadogen Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nomadogen Biotechnologies Inc filed Critical Nomadogen Biotechnologies Inc
Priority to CA2903933A priority Critical patent/CA2903933C/fr
Publication of CA2903933A1 publication Critical patent/CA2903933A1/fr
Application granted granted Critical
Publication of CA2903933C publication Critical patent/CA2903933C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Des méthodes dexpression dun polypeptide dintérêt dans une cellule astrocytaire sont décrites. Les méthodes permettent la localisation et le transport dacides nucléiques dans les exosomes astrocytaires, la reprogrammation des cellules astrocytaires en cellules neuronales et le traitement des victimes daccident ischémique cérébral ou de traumatisme cérébral.
CA2903933A 2015-09-11 2015-09-11 Methodes et compositions de conditionnement d'acides nucleiques dans les exosomes microgliaux destines a l'expression ciblee de polypeptides dans les cellules neuronales Expired - Fee Related CA2903933C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2903933A CA2903933C (fr) 2015-09-11 2015-09-11 Methodes et compositions de conditionnement d'acides nucleiques dans les exosomes microgliaux destines a l'expression ciblee de polypeptides dans les cellules neuronales

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2903933A CA2903933C (fr) 2015-09-11 2015-09-11 Methodes et compositions de conditionnement d'acides nucleiques dans les exosomes microgliaux destines a l'expression ciblee de polypeptides dans les cellules neuronales

Publications (2)

Publication Number Publication Date
CA2903933A1 CA2903933A1 (fr) 2017-03-11
CA2903933C true CA2903933C (fr) 2020-02-25

Family

ID=58232636

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2903933A Expired - Fee Related CA2903933C (fr) 2015-09-11 2015-09-11 Methodes et compositions de conditionnement d'acides nucleiques dans les exosomes microgliaux destines a l'expression ciblee de polypeptides dans les cellules neuronales

Country Status (1)

Country Link
CA (1) CA2903933C (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3162891A1 (fr) * 2019-11-25 2021-06-03 The Penn State Research Foundation Regeneration du cerveau apres une lesion cerebrale traumatique par conversion d'astrocyte en neurone a mediation par neurod1
CN113252616B (zh) * 2021-01-29 2022-05-03 厦门大学 一种外泌体的糖基化研究方法
CN114085816B (zh) * 2021-10-26 2023-05-26 四川大学华西医院 一种标记临近星形胶质细胞的方法
CN114908087B (zh) * 2022-05-07 2024-01-23 四川大学华西医院 一种长循环肾靶向细胞外囊泡的构建及其应用

Also Published As

Publication number Publication date
CA2903933A1 (fr) 2017-03-11

Similar Documents

Publication Publication Date Title
US9840542B2 (en) Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells
CN110291100B (zh) 用于将多肽负荷从细胞外空间递送至靶真核细胞的胞质溶胶和/或细胞核的合理设计的合成肽穿梭剂，其用途、与其相关的方法和试剂盒
US20200317746A1 (en) Targeted and modular exosome loading system
JP4188909B2 (ja) 細胞質残留性細胞膜透過ペプチド及びこれの用途｛ＣｙｔｏｐｌａｓｍｉｃＴｒａｎｓｄｕｃｔｉｏｎＰｅｐｔｉｄｅｓａｎｄＵｓｅｓｔｈｅｒｅｏｆ｝
US20230348537A1 (en) Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
KR101258279B1 (ko) 세포 투과능을 개선한 개량형 신규 거대 분자 전달 도메인 개발 및 이의 이용방법
CA3149413A1 (fr) Agents navettes a base de polypeptides pour l'amelioration de l'efficacite de la transduction de cargos polypeptidiques dans le cytosol de cellules eucaryotes cibles, leurs utilis ations, procedes et trousses les concernant
CA2903933C (fr) Methodes et compositions de conditionnement d'acides nucleiques dans les exosomes microgliaux destines a l'expression ciblee de polypeptides dans les cellules neuronales
JP2009532017A (ja) ＰＴＤ／ＣＰＰＳへのｄｓＲＮＡ結合ドメイン融合体によるｓｉＲＮＡの導入可能な送達
JP6001082B2 (ja) 細胞透過能を改善した改良形の新規巨大分子伝達ドメインの開発及びその利用方法
US11629170B2 (en) Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
CA3156506A1 (fr) Proteines cdkl5 recombinees, therapie genique et procedes de production
CN112218621A (zh) 包含基于靶向亲和域的膜蛋白的胞外囊泡
KR101529634B1 (ko) 역분화 유도를 위한 세포투과성 융합 단백질 및 그 용도
EP4006057A1 (fr) Complexe pour administration intracellulaire de molécules
KR101636538B1 (ko) 인간 ＮＬＢＰ 유래의 ＮＰ2 폴리펩티드 또는 ｄＮＰ2 폴리펩티드를 포함하는 세포 투과 펩티드 및 이를 이용한 카고 전달 시스템
EP4433166A1 (fr) Protéines ancrées par gpi et vésicules extracellulaires les comprenant
KR101912313B1 (ko) Cre 재조합 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 표적 유전자의 조건적 녹아웃 대립유전자를 생성하기 위한 조성물
CN105051061B (zh) 用于扩增干细胞的组合物和方法
KR102671551B1 (ko) 전구약물 전환 효소를 포함하는 개질된 미토콘드리아 및 이의 용도
WO2019189814A1 (fr) Procédé de reprogrammation directe de cellules
KR101564752B1 (ko) 인간 ｎｌｂｐ 단백질 유래의 ｎｐ1 폴리펩티드를 포함하는 세포 투과 펩티드 및 이를 이용한 카고 전달 시스템
US20060099193A1 (en) Methods and materials for suppressing pain

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180110

MKLA Lapsed

Effective date: 20220311

MKLA Lapsed

Effective date: 20200911